Skip to main content
. 2013 Sep 4;10(1):129–137. doi: 10.4161/hv.26269

Table 2. Seroprotection/seropositivity rates at each blood sampling time point (ATP immunogenicity cohorts*).

Study Group   D
%SP		 T
%SP		 PT
%S+		 FHA
%S+		 PRN
%S+		 HBs
%SP		 Polio-1
%SP		 Polio-2
%SP		 Polio-3
%SP		 Hib
%SP
031
n = 141 		DTPa-HBV-IPV/Hib Post 2 100 100 100 100 99.3 96.4 100 97.6 99.2 93.5
Pre 3 86.4 96.4 95.7 100 86.4 95.7 94.4 91.9 80.3 92.8
Post 3 100 100 100 100 99.3 98.6 100 100 100 100
054
n = 177 		DTPa-HBV-IPV/Hib Post 2 97.1 100 100 100 100 98.3 98.8 95.0 99.4 93.7
Pre 3 84.0 94.4 98.1 100 95.5 96.9 89.3 84.5 95.3 90.1
Post 3 100 100 100 100 100 98.9 100 100 100 100
060
n = 80 		DTPa-HBV-IPV/Hib Post 2 96.2 100 97.5 98.7 96.1 98.2 100 97.1 94.3 89.9
Pre 3 NT NT NT NT NT NT NT NT NT NT
Post 3 100 100 100 100 100 100 100 100 100 100
094
n = 228 		DTPa-HBV-IPV/Hib Post 2 NT NT NT NT NT 94.8 NT NT NT 88.3
Pre 3 71.0 92.4 84.2 99.1 91.0 89.7 NT NT NT 79.5
Post 3 100 100 100 100 98.6 99.1 99.5 98.5 97.9 99.1
014/015
n = 314 		DTPa-HBV-IPV/Hib + MenC-TT Post 2 NT NT NT NT NT 95.3 NT NT NT 95.5
Pre 3 NT NT NT NT NT 94.2 NT NT NT 87.4
Post 3 NT NT NT NT NT 99.0 NT NT NT 100
Esposito
n = 275 		DTPa-HBV-IPV/Hib + PCV13 Post 2 92.8 94.2 99.6 100 100 93.8 99.5 95.6 99.5 87.0
Post 3 100 97.6 100 100 100 98.4 100 100 100 99.6
n = 279 DTPa-HBV-IPV/Hib +PCV7 Post 2 96.3 92.5 100 100 100 93.1 99.6 96.6 98.9 90.3
Post 3 100 93.8 100 100 100 98.8 100 100 100 98.2
Durando n = 43 DTPa-HBV-IPV/Hib Post 3 100 100 NT NT NT 97.7 100 100 100 100
n = 151 DTPa-HBV-IPV/Hib + PCV7 Post 3 100 100 NT NT NT 99.3 100 100 100 100

N, number of subjects in ATP cohorts for immunogenicity (total vaccinated cohort for study 060). For Study 094 post-dose-2 blood samples were collected by only 2 centers for testing of anti-PRP and anti-HBs antibodies. NT, blood samples not taken at this time point in the indicated study. SP, seroprotection. For D and T ≥0.1 IU/ml, HBs ≥10 mIU/ml, poliovirus types 1, 2, 3 ≥1:8, Hib ≥0.15μg/ml. S+, seropositivity, for PT, FHA, and PRN ≥5EL.U/ml. *Analysis on the Total vaccinated cohort for study DTPa-HBV-IPV-060.